MOG

MOG Overview

English NameMyelin-oligodendrocyte glycoproteinApproved Drugs0
Drugs in Clinical Trials1Target SynonymNRCLP7,Myelin-oligodendrocyte glycoprotein,MOG,Myelin Oligodendrocyte Glycoprotein,MOG Ig-AluB,MOG Alpha-5,MOG AluA,MOG AluB,BTNL11,MOGIG2,BTN6
Highest Development StagePhase 2 Clinical
English NameMyelin-oligodendrocyte glycoprotein
Target SynonymNRCLP7,Myelin-oligodendrocyte glycoprotein,MOG,Myelin Oligodendrocyte Glycoprotein,MOG Ig-AluB,MOG Alpha-5,MOG AluA,MOG AluB,BTNL11,MOGIG2,BTN6
Approved Drugs0
Drugs in Clinical Trials1
Highest Development StagePhase 2 Clinical

MOG Product List

  • Product Category

    Protein (3)

  • Product Status

    Launched (3)

  • Species

    Human (2)Mouse (1)

  • Tag

    His Tag (1)His Tag & Avi Tag (2)

  • Conjugate

    Unconjugated (1)Biotin-labeled (2)

MOG Background

Myelin oligodendrocyte glycoprotein (MOG), is a single-pass transmembrane glycoprotein of the immunoglobulin (Ig) superfamily. MOG is a myelin protein exclusively expressed in the CNS at the outermost surface of myelin sheaths and oligodendrocyte membranes. This makes MOG a potential target of cellular and humoral immune responses in inflammatory demyelinating diseases. Due to its late postnatal developmental expression, MOG is an important marker for oligodendrocyte maturation.

MOG Synonyms

MOG,BTN6,BTNL11,MOGIG2,NRCLP7,Myelin oligodendrocyte glycoprotein

Clinical Drug Information

English NameResearch CodeHighest Development StageCompanyIndicationClinical Trial
MOG autologous T-lymphocyte cell therapy (ImCyse)Phase 2 ClinicalImcyse SaMultiple Sclerosis
Details
  • Overview
  • Product List
  • Clinical Drug Information
Contact Us

[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521

[North America]: 1 Innovation Way, Newark, DE 19711, USA
[Switzerland]: ACRObiosystems AG, c/o Zug Dammstrasse Centre AG, Dammstrasse 19, 6300 Zug Switzerland